Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

355.48 -2.93 (-0.82%)
Official Closing Price Updated: 7:00 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
West Pharmaceutical Services Q2 Earnings Call Highlights ↗
West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: West Pharmaceutical Servs Q2 2026 Earnings Call ↗
West Pharmaceutical Servs (NYSE:WST) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8%... 
Via StockStory
Topics Economy
West Pharmaceutical Services (NYSE:WST) Shows Explosive Potential with Perfect Minervini Trend Template and Accelerating Growth ↗
Via Chartmill
News headline image
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect. W... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons WST is Risky and 1 Stock to Buy Instead
Over the past six months, West Pharmaceutical Services has been a great trade, beating the S&P 500 by 21.8%. Its stock price has climbed to $353.68, represen... 
Via StockStory
Topics Stocks
News headline image
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 High-Flying Stock Worth Your Attention and 2 Facing Challenges
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
Topics Economy
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Economy
Top S&P500 movers in Tuesday's session ↗
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Q1 Rundown: UFP Technologies (NASDAQ:UFPT) Vs Other Drug Development Inputs & Services Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including UFP Technologies (NASDAQ:UFPT)... 
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
Topics Economy
News headline image
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion ↗
The Microsoft founder's foundation recently added this healthcare stock to its portfolio. 
Via The Motley Fool
News headline image
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Looking back on life sciences tools & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including PacBio (NASDAQ:PACB) and i... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Economy
News headline image
Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Azenta (NASDAQ:AZTA) a... 
Via StockStory
News headline image
1 S&P 500 Stock on Our Buy List and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Economy Stocks
News headline image
Drug Development Inputs & Services Stocks Q1 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato... 
Via StockStory
Topics Economy
News headline image
FDVV vs. NOBL: Which Dividend Stock ETF Is a Better Buy? ↗
A longer track record of dividends doesn't always equate to the best returns. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Find Risky
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
Topics Bonds Economy
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
Topics Economy
News headline image
The Top 5 Analyst Questions From West Pharmaceutical Services’s Q1 Earnings Call
West Pharmaceutical Services delivered a first quarter that exceeded Wall Street's expectations, driven by robust demand for its high-value product (HVP) com... 
Via StockStory
Topics Earnings
News headline image
1 Mooning Stock with Competitive Advantages and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
Topics Economy Retirement
News headline image
WST Q1 Deep Dive: High-Value Components and Operational Execution Drive Outperformance
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 21% year... 
Via StockStory
News headline image
3 Inflated Stocks with Open Questions
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
Topics Economy
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday? ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.